You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 12, 2025

Bayer Hlthcare Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Bayer Hlthcare
International Patents:851
US Patents:39
Tradenames:57
Ingredients:37
NDAs:56

Drugs and US Patents for Bayer Hlthcare

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare GADAVIST gadobutrol SOLUTION;INTRAVENOUS 201277-005 Mar 14, 2011 AP RX Yes Yes ⤷  Try for Free ⤷  Try for Free
Bayer Hlthcare OSMOVIST 240 iotrolan INJECTABLE;INTRATHECAL 019580-002 Dec 7, 1989 DISCN No No ⤷  Try for Free ⤷  Try for Free
Bayer Hlthcare SAFYRAL drospirenone; ethinyl estradiol; levomefolate calcium TABLET;ORAL 022574-001 Dec 16, 2010 AB RX Yes Yes 11,617,751 ⤷  Try for Free Y ⤷  Try for Free
Bayer Hlthcare VITRAKVI larotrectinib sulfate CAPSULE;ORAL 210861-002 Nov 26, 2018 RX Yes Yes ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Bayer Hlthcare

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Hlthcare LEVITRA vardenafil hydrochloride TABLET;ORAL 021400-003 Aug 19, 2003 8,841,446 ⤷  Try for Free
Bayer Hlthcare SAFYRAL drospirenone; ethinyl estradiol; levomefolate calcium TABLET;ORAL 022574-001 Dec 16, 2010 5,798,338 ⤷  Try for Free
Bayer Hlthcare CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER ciprofloxacin INJECTABLE;INJECTION 019857-001 Dec 26, 1990 4,808,583*PED ⤷  Try for Free
Bayer Hlthcare EOVIST gadoxetate disodium SOLUTION;INTRAVENOUS 022090-001 Jul 3, 2008 5,798,092 ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for BAYER HLTHCARE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 2.5 mg ➤ Subscribe 2009-09-04
➤ Subscribe Tablets 200 mg ➤ Subscribe 2014-02-28
➤ Subscribe Tablets 3 mg/0.03 mg/0.451 mg and 0.451 mg ➤ Subscribe 2012-09-28
➤ Subscribe Transdermal System 0.05 mg/day and 0.1 mg/day ➤ Subscribe 2005-09-12
➤ Subscribe Tablets 3 mg/0.02 mg ➤ Subscribe 2006-09-29
➤ Subscribe Injection 1.6 mg/mL ➤ Subscribe 2014-02-07
➤ Subscribe Tablets 0.5 mg, 1 mg,1.5 mg, 2 mg and2.5 mg ➤ Subscribe 2017-10-10
➤ Subscribe Tablets 0.25 mg/0.5 mg ➤ Subscribe 2015-01-08
➤ Subscribe Tablets 3 mg/0.02 mg/0.451 mg and 0.451 mg ➤ Subscribe 2012-11-13
➤ Subscribe Tablets 5 mg ad 10 mg ➤ Subscribe 2009-07-10
➤ Subscribe Tablets 3 mg; 2 mg/2 mg; 2 mg/3 mg; 1 mg ➤ Subscribe 2010-10-22
➤ Subscribe Tablets 25 mg, 50 mg and 100 mg ➤ Subscribe 2005-03-22
➤ Subscribe Tablets 40 mg ➤ Subscribe 2016-09-27
➤ Subscribe Oral Suspension 250 mg/5 mL and 500 mg/ 5 mL ➤ Subscribe 2009-10-16
➤ Subscribe Tablets 3 mg/0.03 mg ➤ Subscribe 2005-01-07
➤ Subscribe Orally Disintegrating Tablets 10 mg ➤ Subscribe 2011-12-22
➤ Subscribe Tablets 0.5 mg/1 mg ➤ Subscribe 2007-12-26
➤ Subscribe Tablets 3 mg/0.02 mg/0.451 mg and 0.451 mg ➤ Subscribe 2011-11-21
➤ Subscribe Tablets 20 mg ➤ Subscribe 2009-03-05

Supplementary Protection Certificates for Bayer Hlthcare Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1429780 SPC/GB12/058 United Kingdom ⤷  Try for Free PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
1140212 33/2014 Austria ⤷  Try for Free PRODUCT NAME: RADIUM-223-DICHLORID; REGISTRATION NO/DATE: EU/1/13/873 20131113
0780390 PA2004012 Lithuania ⤷  Try for Free PRODUCT NAME: MOXIFLOXACINI HYDROCHLORIDUM (1-CIKLOPROPIL-6-FLUOR-__ 1,4-DIHIDRO-8-METOKSI-7-[(4AS, 7AS)-OKTAHIDRO-6H-PIROLO[3,4-B]PIRIDIN_-6-IL]-4-OKSO-3-CHINOLINKARBOKSIRûGðTIES HIDROCHLORIDAS)
1140840 PA2006008,C1140840 Lithuania ⤷  Try for Free PRODUCT NAME: SORAFENIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/06/342/001 20060719
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: Bayer Healthcare – Market Position, Strengths & Strategic Insights

Last updated: February 12, 2025

In the ever-evolving pharmaceutical industry, Bayer Healthcare stands as a formidable player, consistently pushing the boundaries of innovation and strategic growth. As we delve into the competitive landscape of this global pharmaceutical giant, we'll uncover the key factors that contribute to its market position, explore its strengths, and gain valuable strategic insights that drive its success.

Bayer Healthcare: A Global Pharmaceutical Powerhouse

Bayer Healthcare, a division of the larger Bayer AG conglomerate, has established itself as a leading force in the pharmaceutical sector. With a rich history dating back to 1863, the company has built a strong reputation for delivering innovative healthcare solutions across various therapeutic areas.

Market Presence and Global Reach

Bayer Healthcare's global footprint is impressive, with operations spanning over 87 countries and a workforce of approximately 100,000 employees[2]. This extensive reach allows the company to tap into diverse markets and leverage regional opportunities for growth.

Diversified Portfolio

One of Bayer's key strengths lies in its diversified product portfolio, which spans three major segments:

  1. Pharmaceuticals
  2. Consumer Health
  3. Crop Science

This diversification not only helps mitigate risks associated with any particular market segment but also provides multiple avenues for growth and innovation[2].

Bayer's Pharmaceutical Division: A Closer Look

The pharmaceutical division is a cornerstone of Bayer Healthcare's operations, contributing significantly to the company's overall revenue and market position.

Key Therapeutic Areas

Bayer's pharmaceutical portfolio focuses on several critical therapeutic areas, including:

  • Cardiovascular diseases
  • Oncology
  • Ophthalmology
  • Women's health
  • Pulmonary hypertension[7]

This targeted approach allows Bayer to concentrate its resources on areas with high unmet medical needs and significant market potential.

Innovative Product Pipeline

Bayer's commitment to innovation is evident in its robust product pipeline. The company has over 80 new potential medicines and crop science solutions in development[2]. This pipeline is crucial for maintaining a competitive edge in the rapidly evolving pharmaceutical landscape.

"We've rapidly scaled the new operating model and significantly leveled up the Pharma pipeline," said Chief Executive Officer Bill Anderson[1].

Market Position and Financial Performance

Bayer Healthcare's market position remains strong, with the company consistently ranking among the top pharmaceutical companies globally.

Sales Performance

In the third quarter of 2024, Bayer reported sales that were level with the prior-year period on a currency- and portfolio-adjusted basis[1]. The pharmaceutical division, in particular, showed resilience:

  • Sales of prescription medicines (Pharmaceuticals) rose by 2.3% (Fx & portfolio adj.) to 4.510 billion euros[1].
  • New products achieved significant gains, with growth rates of 83.2% (Fx & portfolio adj.) for Nubeqa™ and 96.4% (Fx & portfolio adj.) for Kerendia™[1].

Market Valuation

Bayer's brand value is estimated at approximately €15.2 billion as of 2023, reinforcing its strong market position and consumer trust[2].

Strengths and Competitive Advantages

Bayer Healthcare's success in the pharmaceutical landscape can be attributed to several key strengths:

1. Strong Research and Development Capabilities

Bayer's commitment to R&D is evident in its substantial investment. In 2022, the company invested approximately €5.3 billion in research and development, amounting to about 6.9% of its total sales[2]. This significant investment fuels innovation and helps maintain a competitive edge.

2. Established Brand Reputation

With a history spanning over 150 years, Bayer has built a strong brand reputation that instills trust among consumers, healthcare professionals, and investors alike[2].

3. Diverse Product Portfolio

Bayer's diverse range of products across pharmaceuticals, consumer health, and crop science helps mitigate risks and capitalize on various market opportunities[7].

4. Global Presence

Operating in over 90 countries, Bayer's global reach allows it to tap into various markets and benefit from different economic conditions[7].

5. Focus on Biologics

Bayer's growing number of biologic drugs, such as Betaferon for multiple sclerosis and Kogenate for hemophilia, provides a competitive advantage due to the manufacturing complexity that deters generic competition[3].

Strategic Insights and Future Outlook

To maintain its competitive position and drive future growth, Bayer Healthcare is focusing on several strategic initiatives:

1. Digital Transformation

Bayer is actively tapping into emerging technologies, including digital therapeutics, real-world data, and artificial intelligence, to expand beyond traditional drug discovery and development[4].

2. Expansion into Emerging Markets

The company is strategically focusing on regions such as China and India, where healthcare spending is expected to rise significantly. In China alone, healthcare spending is projected to surpass $1 trillion by 2025[2].

3. Sustainable Agriculture Solutions

Bayer is capitalizing on the growing demand for sustainable agricultural solutions and bio-based products. The global market for sustainable agricultural solutions is anticipated to reach $24 billion by 2026[2].

4. Focus on Launch Products

Bayer is confident in the growth momentum of its launch products, particularly the cancer drug Nubeqa™ and Kerendia™ for chronic kidney disease associated with type 2 diabetes[1].

5. Pipeline Advancement

The company is targeting 2025 market launches for acoramidis and elinzanetant, further strengthening its product portfolio[1].

Challenges and Market Pressures

Despite its strong position, Bayer Healthcare faces several challenges in the competitive pharmaceutical landscape:

1. Patent Expirations

The loss of exclusivity for key products, such as Xarelto™, is expected to put pressure on the company's EBITDA margin[1].

2. Regulatory Challenges

Increasing regulatory scrutiny and challenges in the pharmaceutical industry pose potential risks to Bayer's operations and product approvals[7].

3. Pricing Pressures

The company continues to face pricing pressure in its crop protection business, which has led to a lowering of 2024 targets for Crop Science[1].

4. Market Competition

Bayer operates in highly competitive markets, facing competition from both established players and emerging companies[7].

Key Takeaways

  1. Bayer Healthcare maintains a strong market position with a diverse product portfolio spanning pharmaceuticals, consumer health, and crop science.

  2. The company's commitment to R&D and innovation, evidenced by its €5.3 billion investment in 2022, drives its competitive advantage.

  3. Bayer's global presence in over 87 countries allows it to capitalize on diverse market opportunities.

  4. Strategic focus on digital transformation, emerging markets, and sustainable solutions positions Bayer for future growth.

  5. Despite challenges such as patent expirations and pricing pressures, Bayer's robust pipeline and launch products show promise for continued success.

FAQs

  1. Q: What are Bayer Healthcare's key therapeutic areas in pharmaceuticals? A: Bayer focuses on cardiovascular diseases, oncology, ophthalmology, women's health, and pulmonary hypertension.

  2. Q: How much does Bayer invest in research and development? A: In 2022, Bayer invested approximately €5.3 billion in R&D, about 6.9% of its total sales.

  3. Q: What are some of Bayer's fastest-growing pharmaceutical products? A: Nubeqa™ (for cancer) and Kerendia™ (for chronic kidney disease associated with type 2 diabetes) have shown significant growth rates of 83.2% and 96.4%, respectively.

  4. Q: How is Bayer adapting to digital transformation in healthcare? A: Bayer is actively exploring digital therapeutics, real-world data, and artificial intelligence to enhance its product offerings and improve operational efficiency.

  5. Q: What are the main challenges Bayer faces in the pharmaceutical market? A: Key challenges include patent expirations, regulatory pressures, pricing challenges in certain segments, and intense market competition.

Sources cited: [1] https://www.bayer.com/media/en-us/bayer-strategic-progress-in-challenging-business-environment--group-outlook-confirmed-in-nearly-all-parameters/ [2] https://canvasbusinessmodel.com/products/bayer-swot-analysis [3] https://www.morningstar.com/personal-finance/we-see-steady-growth-bayer [4] https://www.cbinsights.com/research/bayer-healthcare-strategy-map-investments-partnerships-acquisitions/ [7] https://pitchgrade.com/companies/bayer-ag

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.